ACA
CRSP icon

Atlas Capital Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Atlas Capital Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,600
Closed -$121K – 923
2021
Q4 		$121K Hold
1,600
– – 0.02% 425
2021
Q3 		$179K Sell
1,600
-1,600
-50% -$201K 0.03% 357
2021
Q2 		$518K Buy
+3,200
New +$389K 0.09% 199

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Atlas Capital Advisors's CRSP Position: Q1 2022 in Review

Atlas Capital Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 1,600 shares — an estimated $121K sold.

Atlas Capital Advisors first reported a position in CRSP in Q2 2021 and held it in 3 quarters. The position peaked at $518K in Q2 2021. 447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

  • Atlas Capital Advisors reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Atlas Capital Advisors sold 1,600 CRISPR Therapeutics shares in Q1 2022, an estimated $121K.
  • Atlas Capital Advisors first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 3 quarters.
  • Atlas Capital Advisors's CRISPR Therapeutics position peaked at $518K in Q2 2021.
  • 447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Atlas Capital Advisors's 13F filing for Q1 2022, filed 11 May 2022.